RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Rallybio Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$16.35+0.07 (+0.43%)

Close on Oct 19, 2026

Market cap: $94.80M
P/E (TTM): 2.1
Dividend yield: –

Dividends

Rallybio has not reported a dividend

No dividend per share appears in Rallybio's annual filings since fiscal 2019.

Where these numbers come from

Parsed from the XBRL in Rallybio's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-8 reverse split on Mar 16, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RLYB.

Revenue growth-15.1% · median -34.3%

Operating margin-4291.5% · median -7264.1%

Net margin7051.2% · median -6677.2%

Company	Revenue	Growth
STTK	$1.00M	-66.6%
RLYB	$646.00K	-15.1%
SLN	$615.00K	-97.7%
VCNX	$601.00K	+5.4%
YARW	$476.00K	-2.1%
MREO	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 14
Held by institutions: 100.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 1739410

Advertisement
300 × 250